Table 3:
Ongoing Phase III combination studies for metastatic RCC
| Therapy | Study | Mechanism of Action | Population | End point |
|---|---|---|---|---|
| Bevacizumab + Atezolizumab | IMmotion151 NCT02420821 |
VEGF+PD-L1 | Untreated metastatic RCC with clear cell and sarcomatoid histology | PFS, PD in PD-L1+ OS in overall pop |
| Pembrolizumab + Lenvatinib | CLEAR NCT02811861 |
PD-1 + TKI | Untreated & treated metastatic ccRCC | PFS |
| Nivolumab + Cabozantinib ± Ipilimumab | CHECKMATE 9ER NCT03141177 |
PD-1 + TKI | Untreated metastatic or one prior non-VEGF/VEGFR neo/adjuvant treated metastatic ccRCC | PFS |
OS: overall survival; PFS: progression-free survival; PD: disease progression; TKI: tyrosine kinase inhibitor; PD-1: program death 1; ccRCC: clear cell renal cell carcinoma